Maryland

Recommendations were provided to the Board for interventions to be initiated in the fourth quarter of 2019, and include overutilization of gabapentin (dosing recommendations for Gabapentin IR, GraliseĀ®, and HorizantĀ®), concurrent use of gabapentin and pregabalin, concurrent use of an opioids and medium-high dose gabapentin and non-adherence ... ................
................